On January 16th, Jinshi Data reported that the Hong Kong stock market’s Xinda Biology (01801.HK) experienced a flash crash, with the stock price falling by more than 14% at one point. Regarding the above dynamics, Xinda Biology stated to reporters that the company’s stock price and trading volume had abnormal fluctuations in the afternoon, but the company’s business operations are normal and there have been no changes; Currently, the company’s products under review, such as Mastinib, Tuzumab, and Pikangqibai, are progressing smoothly and have not changed.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Sinotrans Biotechnology responds to stock price flash crash: everything is normal with the company and the progress of products under review.
On January 16th, Jinshi Data reported that the Hong Kong stock market’s Xinda Biology (01801.HK) experienced a flash crash, with the stock price falling by more than 14% at one point. Regarding the above dynamics, Xinda Biology stated to reporters that the company’s stock price and trading volume had abnormal fluctuations in the afternoon, but the company’s business operations are normal and there have been no changes; Currently, the company’s products under review, such as Mastinib, Tuzumab, and Pikangqibai, are progressing smoothly and have not changed.